Press Resease

Hydroxychloroquine Market - By Type (USP Standards Grade, Pharmaceutical Standards Grade, EP Standards Grade, and Others), By Application (Rheumatoid Arthritis, Skin Lesions, Systemic Lupus Erythematosus, Chronic Discoid Lupus Erythematosus, and Others), and By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2025

Published Date: 15-Apr-2020 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-5346 Status : Published

Global Hydroxychloroquine market value was estimated at 542 (USD Million) in 2019 and is projected to hit 5,000 (USD Million) by 2025 growing at a CAGR of over 33% during the period from 2019 to 2025.

Description

The global Hydroxychloroquine market value was estimated at 542 (USD Million) in 2019 and is projected to hit 5,000 (USD Million) by 2025 growing at a CAGR of over 33% during the period from 2019 to 2025. The report offers valuation and analysis of the Hydroxychloroquine market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, restraints, revenue estimates, avenues, current & emerging trends, and industry-validated market information. The report offers historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on value (USD Million).

Introduction

Hydroxychloroquine also referred as Hydroxychloroquine phosphate is the drug that is used for treating malaria and certain auto-immune disorders including lupus & rheumatoid arthritis. Moreover, the medicine is the part of disease modifying anti-rheumatic drugs. It has the ability for alleviating skin problems in lupus and avoiding pain or swelling caused due to arthritis. However, the drug is not approved by the U.S. FDA to treat coronavirus.

Hydroxychloroquine Market

Furthermore, Hydroxychloroquine is recently studied as the best possible drug for treating COVID-19. The generic form of the drug is also available and it can also be taken orally. The medicine can also be utilized as a part of combination therapy.  Its medical application was approved in the U.S. during 1955 to treat many chronic diseases.

Details of the Report:

Report Metric

Details

Base Year

2018

Historical Data

2016 and 2017

Forecast period

2019-2025

Market Representation

Earnings provided in terms of USD Million and CAGR estimated from 2019 to 2025

Segments Analyzed

By Type, By Application, and By Region

Regions Analyzed

North America, Asia Pacific, Latin America, Europe, and the Middle East and Africa

Market Growth Dynamics

According to NIH, Hydroxychloroquine is used for treating malaria as well as rheumatoid conditions. Various studies conducted by NIH concluded that the medicine displayed anti-viral features and the capability to alter immune system activities along with establishing of safe profile at apt dosages. This, in turn, is likely to enhance the drug potential and its effectiveness in treating novel coronavirus.

Moreover, Hydroxychloroquine is found to have less side effects and low toxicity even if overdosed. Apparently, developed nations has good supply of the drug due to huge presence of the drug manufacturers in these nations.  Reportedly, when the combination of Hydroxychloroquine and azithromycin drug treatment was given to nearly 40 COVID -19 patients in France, it helped in clearing the virus from their bodies and this was concluded through the nasal swabs samples of the patients. For the record, the U.S. has been using it as a preventive medicine against COVID-19 recently.

Hospitals in the U.S. are storing the drug after the U.S. president termed the drug as the game-changer in treating of coronavirus. Even some countries of Europe along with China and South Korea have recommended the use of the drug for treating COVID-19 patients. Moreover, the drug has been advocated in countries like India as a measure to prevent the coronavirus in people who have been in contact with COVID positive persons and those falling in high risk zone. All these aforementioned aspects are likely to favorably leverage the growth of the Hydroxychloroquine market over the forecast period.

Asia Pacific To Contribute Lucratively Towards Market Share By 2025

The growth of the Hydroxychloroquine market in the region can be attributed to India being the leading producer of the drug and China being the largest exporter of the raw materials for the drug production. Apart from this, it is cost-effective drug in India costing nearly lesser than rupees three per tablet.

According to Forbes, India produces 70% of the drug and had banned it in March 2020. However, U.S. President Trump requested for the supply of the drug from India as he considered it a game-changer in medicine history and treating coronavirus. For the record, the U.S. government has placed an order of 29 million doses of the drug to be imported from India. This resulted in the lifting of export ban by the country for India’s neighbors as well as the U.S. Apart from this, nearly 36 countries have demanded the drug and this included Italy, Spain, Australia, Germany, Israel, Indonesia and the U.S. These abovementioned factors will drive the business growth in Asia Pacific over the forthcoming years.

As per the authentic sources, India is expected to export the drugs to more than 20 countries including Mauritius, U.S., Canada, Seychelles, Brazil, UK, Bangladesh, Spain, Afghanistan, Germany, France, Bahrain, Australia, Nepal, Bhutan, Maldives, Dominican Republic, Israel, New Zealand and South Africa for helping these countries combat novel coronavirus effectively. This aspect will create lucrative growth avenues for the market in the Asia Pacific over the ensuing years.

Furthermore, presence of leading API manufacturers such as Mangalam Drugs, Laurus Labs, Abbott India, Rusan Pharma, Unichem Remedies, and Vijayasri Organics in India will contribute notably towards the market earnings in Asia Pacific region. The country also has the established presence of key drug manufacturers like IPCA, Laurus Labs, and Zydus Cadila.

Key players profiled in the report include Teva, Mylan, Novartis, Cadila Healthcare, Torrent Pharma, Shanghai Zhongxisanwei, BSE healthcare, Sandoz, HIKMA, IPCA Laboratories, Cipla Limited, Shanghai Pharma, Intas Pharmaceuticals, Lupin Limited, Shenhua Pharm, Sanofi, H-QYN, Macleod Pharmaceuticals, McW Healthcare, Laurus Labs, TAJ Pharma, Wuhan Wuyao Pharmaceutical, MAAN Medex, Cinkate, and Concordia Healthcare.

The global Hydroxychloroquine market is segmented as follows:

By Type

  • USP Standards Grade
  • Pharmaceutical Standards Grade
  • EP Standards Grade
  • Others

By Application

  • Rheumatoid Arthritis
  • Skin Lesions
  • Systemic Lupus Erythematosus
  • Chronic Discoid Lupus Erythematosus
  • Others

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Hydroxychloroquine Market, 2016–2025 (USD Million)
    • 2.2. Hydroxychloroquine Market: Snapshot
  • Chapter 3. Global Hydroxychloroquine Market– Industry Analysis
    • 3.1. Hydroxychloroquine Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Anti-viral characteristics of the drug and ability to change immune system activity will drive the business landscape
      • 3.2.2. Beneficial features such as lower side effects and toxicity will enlarge the market scope over the forecast period
    • 3.3. Porter’s Five Forces Analysis
    • 3.4. Market Attractiveness Analysis
      • 3.4.1. Market attractiveness analysis By Type
      • 3.4.2. Market attractiveness analysis By Application
  • Chapter 4. Global Hydroxychloroquine Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Hydroxychloroquine Market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Hydroxychloroquine Market–Type Analysis
    • 5.1. Global Hydroxychloroquine Market overview: By Type
      • 5.1.1. Global Hydroxychloroquine Market share, By Type,2018 and 2025
    • 5.2. USP Standards Grade
      • 5.2.1. Global Hydroxychloroquine Market by USP Standards Grade, 2016–2025 (USD Million)
    • 5.3. Pharmaceutical Standards Grade
      • 5.3.1. Global Hydroxychloroquine Market by Pharmaceutical Standards Grade, 2016–2025 (USD Million)
    • 5.4. EP Standards Grade
      • 5.4.1. Global Hydroxychloroquine Market by EP Standards Grade, 2016–2025 (USD Million)
    • 5.5. Others
      • 5.5.1. Global Hydroxychloroquine Market by Others, 2016–2025 (USD Million)
  • Chapter 6. Global Hydroxychloroquine Market– Application Analysis
    • 6.1. Global Hydroxychloroquine Market overview: By Application
      • 6.1.1. Global Hydroxychloroquine Market share, By Application, 2018 and 2025
    • 6.2. Rheumatoid Arthritis
      • 6.2.1. Global Hydroxychloroquine Market By Rheumatoid Arthritis, 2016–2025 (USD Million)
    • 6.3. Skin Lesions
      • 6.3.1. Global Hydroxychloroquine Market By Skin Lesions, 2016–2025 (USD Million)
    • 6.4. Systemic Lupus Erythematosus
      • 6.4.1. Global Hydroxychloroquine Market By Systemic Lupus Erythematosus, 2016–2025 (USD Million)
    • 6.5. Chronic Discoid Lupus Erythematosus
      • 6.5.1. Global Hydroxychloroquine Market By Chronic Discoid Lupus Erythematosus, 2016–2025 (USD Million)
    • 6.6. Others
      • 6.6.1. Global Hydroxychloroquine Market By Others, 2016–2025 (USD Million)
  • Chapter 7. Company Profiles
    • 7.1. Teva
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Product Portfolio
      • 7.1.4. Business Strategy
      • 7.1.5. Recent Developments
    • 7.2. Mylan
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Product Portfolio
      • 7.2.4. Business Strategy
      • 7.2.5. Recent Developments
    • 7.3. Novartis
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Product Portfolio
      • 7.3.4. Business Strategy
      • 7.3.5. Recent Developments
    • 7.4. Cadila Healthcare
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Product Portfolio
      • 7.4.4. Business Strategy
      • 7.4.5. Recent Developments
    • 7.5. Torrent Pharma
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Product Portfolio
      • 7.5.4. Business Strategy
      • 7.5.5. Recent Development
    • 7.6. Shanghai Zhongxisanwei
      • 7.6.1. Overview
      • 7.6.2. Financials
      • 7.6.3. Product Portfolio
      • 7.6.4. Business Strategy
      • 7.6.5. Recent Development
    • 7.7. BSE healthcare
      • 7.7.1. Overview
      • 7.7.2. Financials
      • 7.7.3. Product Portfolio
      • 7.7.4. Business Strategy
      • 7.7.5. Recent Development
    • 7.8. Sandoz
      • 7.8.1. Overview
      • 7.8.2. Financials
      • 7.8.3. Product Portfolio
      • 7.8.4. Business Strategy
      • 7.8.5. Recent Development
    • 7.9. HIKMA
      • 7.9.1. Overview
      • 7.9.2. Financials
      • 7.9.3. Product Portfolio
      • 7.9.4. Business Strategy
      • 7.9.5. Recent Development
    • 7.10. IPCA Laboratories
      • 7.10.1. Overview
      • 7.10.2. Financials
      • 7.10.3. Product Portfolio
      • 7.10.4. Business Strategy
      • 7.10.5. Recent Development
    • 7.11. Cipla Limited
      • 7.11.1. Overview
      • 7.11.2. Financials
      • 7.11.3. Product Portfolio
      • 7.11.4. Business Strategy
      • 7.11.5. Recent Development
    • 7.12. Shanghai Pharma
      • 7.12.1. Overview
      • 7.12.2. Financials
      • 7.12.3. Product Portfolio
      • 7.12.4. Business Strategy
      • 7.12.5. Recent Development
    • 7.13. Intas Pharmaceuticals
      • 7.13.1. Overview
      • 7.13.2. Financials
      • 7.13.3. Product Portfolio
      • 7.13.4. Business Strategy
      • 7.13.5. Recent Development
    • 7.14. Lupin Limited
      • 7.14.1. Overview
      • 7.14.2. Financials
      • 7.14.3. Product Portfolio
      • 7.14.4. Business Strategy
      • 7.14.5. Recent Development
    • 7.15. Shenhua Pharm
      • 7.15.1. Overview
      • 7.15.2. Financials
      • 7.15.3. Product Portfolio
      • 7.15.4. Business Strategy
      • 7.15.5. Recent Development
    • 7.16. Sanofi
      • 7.16.1. Overview
      • 7.16.2. Financials
      • 7.16.3. Product Portfolio
      • 7.16.4. Business Strategy
      • 7.16.5. Recent Development
    • 7.17. H-QYN
      • 7.17.1. Overview
      • 7.17.2. Financials
      • 7.17.3. Product Portfolio
      • 7.17.4. Business Strategy
      • 7.17.5. Recent Development
    • 7.18. H-QYN
      • 7.18.1. Overview
      • 7.18.2. Financials
      • 7.18.3. Product Portfolio
      • 7.18.4. Business Strategy
    • 7.19. Macleod Pharmaceuticals
      • 7.19.1. Overview
      • 7.19.2. Financials
      • 7.19.3. Product Portfolio
      • 7.19.4. Business Strategy
    • 7.20. McW Healthcare
      • 7.20.1. Overview
      • 7.20.2. Financials
      • 7.20.3. Product Portfolio
      • 7.20.4. Business Strategy
      • 7.20.5. Recent Development
    • 7.21. Laurus Labs
      • 7.21.1. Overview
      • 7.21.2. Financials
      • 7.21.3. Product Portfolio
      • 7.21.4. Business Strategy
      • 7.21.5. Recent Development
    • 7.22. TAJ Pharma
      • 7.22.1. Overview
      • 7.22.2. Financials
      • 7.22.3. Product Portfolio
      • 7.22.4. Business Strategy
      • 7.22.5. Recent Development
    • 7.23. Wuhan Wuyao Pharmaceutical
      • 7.23.1. Overview
      • 7.23.2. Financials
      • 7.23.3. Product Portfolio
      • 7.23.4. Business Strategy
      • 7.23.5. Recent Development
    • 7.24. MAAN Medex
      • 7.24.1. Overview
      • 7.24.2. Financials
      • 7.24.3. Product Portfolio
      • 7.24.4. Business Strategy
      • 7.24.5. Recent Development
    • 7.25. Cinkate
      • 7.25.1. Overview
      • 7.25.2. Financials
      • 7.25.3. Product Portfolio
      • 7.25.4. Business Strategy
      • 7.25.5. Recent Development
    • 7.26. Concordia Healthcare
      • 7.26.1. Overview
      • 7.26.2. Financials
      • 7.26.3. Product Portfolio
      • 7.26.4. Business Strategy
      • 7.26.5. Recent Development

Methodology


Frequently Asked Questions

The key growth drivers that will influence the market expansion will be the anti-viral properties of the drug along with its low toxicity & lesser side effects

The CAGR of the market is expected to be nearly over 33% during the forecast period.

Asia Pacific region will influence the global market demand over the estimated timeline.

India is the leading producer of the drug with IPCA labs and Zydus Cadilla having high backward integrated manufacturing capacity.

The key market participants include Teva, Mylan, Novartis, Cadila Healthcare, Torrent Pharma Laurus Labs, TAJ Pharma, Wuhan Wuyao Pharmaceutical, MAAN Medex, Cinkate, and Concordia Healthcare.

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Accept

We have secured system to process your transaction.


We Are On Social